先前有研究表明产ESBL-E. coli在对厄他培南产生耐药性的同时,也会对其他碳青霉烯类抗生素产生交叉耐药,引发了人们对结构相似的青霉烯类与碳青霉烯类抗生素交叉耐药的关注。本研究中作者通过体外诱导大肠杆菌的法罗培南耐药后进行药敏实验,...
[3] Harris PNA, Tambyah PA, Lye DC, et al. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial [published correction appears in JAMA. 2019 Jun 18;321(2...
ESBL-producing E. coli are an important public health concern and have been labeled by the CDC as a serious threat to public health. This bacterium causes thousands of death each year and therefore novel therapeutic approaches (e.g. microbiome-based solutations) are needed, especially with the...
美国疾病控制和预防中心(CDC)在《2019年抗生素耐药威胁报告》中将ESBL-E列为严重级别的威胁[1]。近期有研究表明,与其他β-内酰胺类药物,特别是哌拉西林-他唑巴坦相比,碳青霉烯类药物治疗ESBL-E引起的血流感染(BSI)的死亡率更低[2-4]。随后,美国感染病学会(IDSA)发布了一份关于治疗耐药革兰阴性杆菌感染的指导文...
“While CRE and ESBL-E have been extensively studied in adults, few studies have described the epidemiology of these bacteria in children,”Alice Y. Guh, MD, MPH,a medical officer in the Division of Healthcare Quality Promotion at the CDC, said in an interview. “Therefore, to bet...
43.6% 肠杆菌科产ESBLs比例 2008 大肠杆菌 56.2% 肺杆 43.6% 奇异变形 16.9% E.coli/ELBLs ESBLs(+,-)菌株耐药率 大肠杆菌 肺杆 奇异变形 E+ E- E+ E- E+ E- 噻肟 87.1 7.6 80.4 8.3 64.0 5.4 他定 27.3 2.8 51.3 8.1 27.9 4.8 吡肟 32.9 2.6 37.1 4.1 27.9 4.3 哌拉 98.3 49.9 98.2 28....
社区获得性感染社区获得性感染病人分离的革兰病人分离的革兰阴性菌共阴性菌共20992099株株2099株革兰阴性菌分布株革兰阴性菌分布antimicrobagentschemother.2006jan;50(1):374-8.主要肠杆菌科细菌耐药性主要肠杆菌科细菌耐药性all(1651)e. coli(953)klebsiella(357)enterobactercitrobacter, serratia (175)esbl 13、+?
43:1407–1414.OngoingClinicalStudyonAlternativestoCarbapeneminESBL-producingBacterialInfectionsβ-Lactam/β-LactamInhibitorCombinationsfortheTreatmentofBacteremiaDuetoESBL–ProducingEcoli:APostHocAnalysisofProspectiveCohortsESBL-ECisanimportantcauseofinvasiveinfections.Alternativestocarbapenems—consideredthedrugsofchoice—...
()Pip/tazCiprofloxacinAntimicrob Agents Chemother. 2006 Jan;50(1):374-8.Species Distribution of GNB Causing IAIs 2,292 Isolates, China, SMART, 2002-2007Rates of ESBL-producing E. coli and K. pneumoniae f 革兰阴性菌感染治疗需关注esbls广州 来自淘豆网www.taodocs.com转载请标明出处.猜你喜欢...
“感控研讨会” 等; HA-MDROs感染干预实效 Founier 2010 submitted 95% CI 25.0 6.3 PDR-AB感染 55.8 62.2 ESBLs kp感染 56.9 65.2 ESBLs E coli感染 8.9 26.4 VRE感染 74.0 77.5 MRSA 感染 08.6-09.5 07.6-08.5 感染分类 HA-MDROs感染检出率(%) The “12 Steps to Prevent Antimicrobial Resistance: ...